Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
To be eligible for the BELIEVE study, participants must have a body mass index (BMI) greater than or equal to 30, or greater than or equal to 27 with one or more obesity-related comorbidities
Generally, individuals who are considered obese or patients who are overweight with the presence of one or multiple weight-related health conditions, may qualify for Semaglutide GLP-1
These include people with type 2 diabetes or higher blood sugar, people with a history of cancer, and people with eye conditions like diabetic retinopathy
Tirzepatide is a dual GIP and GLP-1 receptor agonist built from a specific sequence of 39 amino acids, and each of those amino acid residues is vulnerable to chemical modification under the wrong conditions
US$ 25.86
US$ 29.38
US$ 25.07
US$ 26.53
